Publications by authors named "Daniela Verri"
Article Synopsis
- Childhood interstitial lung disease (chILD) includes over 200 rare lung disorders with no approved treatments and varying outcomes; this study investigates nintedanib, a drug that has shown promise in adults with similar diseases, in children aged 6-17 with fibrosing chILD.
- The trial is a multicenter, double-blind, randomized, placebo-controlled study where participants will take oral nintedanib or a placebo for 24 weeks, with dosing based on body weight and flexibility for dose adjustments if side effects arise.
- Primary endpoints focus on the drug's pharmacokinetics and side effects at week 24, while secondary endpoints assess changes in lung function, quality of life, oxygen levels, and walking
We present results from the first phase III trial of once-daily tiotropium add-on to inhaled corticosteroids (ICS) plus one or more controller therapies in adolescents with severe symptomatic asthma.In this double-blind, parallel-group trial (NCT01277523), 392 patients aged 12-17 years were randomised to receive once-daily tiotropium 5 µg or 2.5 µg, or placebo, as an add-on to ICS plus other controller therapies over 12 weeks.
View Article and Find Full Text PDFBackground: Patients with Restless Legs Syndrome (RLS) often seek treatment because of sleep problems related to nocturnal symptoms. Our goal was to test the ability of pramipexole to improve sleep in RLS patients and to reconfirm its efficacy for primary RLS symptoms.
Methods: Adults with moderate or severe RLS were randomized to receive placebo or pramipexole (flexibly titrated from 0.